- Percutaneous exclusion of the left atrial appendage in preventing systemic embolization2011 | Faculty of Medicine in Hradec Králové
- Percutaneous exclusion of the left atrial appendage in prevention of systemic embolism2012 | Faculty of Medicine in Hradec Králové
- Rare cause of recurrent systemic embolism in a middle-aged woman with undiagnosed lung A-V malformation2019 | First Faculty of Medicine
- Cost-effectiveness analysis of first-line NOAC prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation2019 | First Faculty of Medicine, Second Faculty of Medicine
- The heart as a source of systemic embolization2017 | First Faculty of Medicine
- Myxoma of the Left Atrium - the Cause of Repeated Systemic Embolization1994 | First Faculty of Medicine
- Aczte staphylococcus endocarditis of mitral valve with perforation of front lap and systemic embolizationPublication without faculty affiliation
- Apixaban (Eliquis(R)) was registered also for stroke and systemic embolic events prevention in atrial fibrillation patients by the end of 20122013 | First Faculty of Medicine
- Clinical manifestations of infective endocarditis in relation to infectious agents: An 8-year retrospective study2016 | Publication without faculty affiliation
- Unrecognized infective endocarditis in a young woman2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Dabigatran-etexilate (Pradaxa®) in prevention of strokes in patients with atrial fibrillation2012 | Publication without faculty affiliation
- Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease2018 | Publication without faculty affiliation
- Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry2023 | Faculty of Medicine in Pilsen
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BAY59-7939/11630Publication without faculty affiliation
- The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial2016 | Publication without faculty affiliation
- Edoxaban - new FXa inhibitor2017 | Publication without faculty affiliation
- Apixaban in patients with atrial fibrillation and impaired renal function - subanalysis of ARISTOTLE study2013 | Publication without faculty affiliation
- Long-term experience with dabigatran anticoagulation therapy in atrial fibrilation. RELY-ABLE study2013 | Publication without faculty affiliation
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation2009 | Second Faculty of Medicine
- ARISTOTLE study - another milestone in anticoagulation therapy for atrial fibrillation2012 | Publication without faculty affiliation
- Dabigatran etexilate - a new promising antithrombotic agent2010 | First Faculty of Medicine, Third Faculty of Medicine
- Dabigatran in the prevention of stroke in patients with atrial fibrilation2011 | First Faculty of Medicine, Third Faculty of Medicine
- Treatment of emergencies associated with bleeding risk in patients taking new oral anticoagulants - options concerning termination of their effect2016 | First Faculty of Medicine, Third Faculty of Medicine
- What the cardiologist should know about the treatment of vascular diseases2013 | First Faculty of Medicine, Third Faculty of Medicine
- Anticoagulant Therapy in the Prevention and Treatment of Ischemic Stroke2010 | First Faculty of Medicine
- Novel (direct) oral anticoagulants in the practice - indications, dosage, advantages, and drawbacks2017 | Faculty of Medicine in Pilsen
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study2013 | Publication without faculty affiliation
- Rhythm versus rate control in patients with newly diagnosed atrial fibrillation - Observations from the GARFIELD-AF registry2023 | Publication without faculty affiliation
- New peroral antithrombotics in the prevention and treatment of tromboembolism2012 | First Faculty of Medicine, Third Faculty of Medicine
- Dabigatran etexilate - a breakthrough in antithrombotic therapy in cardiology?2011 | Publication without faculty affiliation